You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relative Dose Intensity of Adjuvant Chemotherapy in Older ER+

Not yet recruiting
  • Breast Cancer
    • (no location specified)
    Aug 21, 2023

    HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

    Not yet recruiting
    • HER2-positive Breast Cancer
    • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
    • (no location specified)
    Jul 20, 2023

    HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)

    Not yet recruiting
    • HR+/HER2- Breast Cancer
    • (no location specified)
    Nov 21, 2022

    HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

    Recruiting
    • HR Positive HER2 Negative Advanced Breast Cancer
    • Tianjin, China
      天津市肿瘤医院
    May 26, 2023

    Breast Cancer Trial in Tianjin (Pyrrolidine?trastuzumab?AI)

    Recruiting
    • Breast Cancer
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Jun 1, 2023

    Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

    Recruiting
    • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jun 12, 2023

    Metastatic Breast Cancer Trial (SKB264, Eribulin, Capecitabine)

    Not yet recruiting
    • Metastatic Breast Cancer
    • (no location specified)
    Oct 7, 2023

    Breast Cancer Trial in Shantou (dose-dense nab-paclitaxel followed by EC)

    Recruiting
    • Breast Cancer
    • dose-dense nab-paclitaxel followed by EC
    • Shantou, Guangdong, China
      Shantou Central Hospital
    Feb 4, 2023

    HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

    Not yet recruiting
    • HR+/HER2-breast Cancer
    • Standard endocrine therapy plus Apatinib
    • (no location specified)
    Jun 2, 2023

    Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

    Recruiting
    • Breast Cancer
    • pyrotinib combined with trastuzumab, dalpiciclib and letrozole
    • Yantai, Shandong, China
      Yantai Yuhuangding Hospital
    Mar 23, 2023

    HER2-positive Breast Cancer Trial in Birmingham ([18F]FMISO PET/MRI imaging)

    Recruiting
    • HER2-positive Breast Cancer
    • [18F]FMISO PET/MRI imaging
    • Birmingham, Alabama
      The University of Alabama at Birmingham
    Dec 8, 2022

    Breast Cancer Trial in Ann Arbor (Ribociclib, Postoperative Radiation Therapy)

    Not yet recruiting
    • Breast Cancer
    • Ann Arbor, Michigan
      University of Michigan
    Aug 10, 2023

    Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

    Not yet recruiting
    • Hormone Receptor-positive Advanced Breast Cancer
    • chidamide combined with fulvestrant
    • (no location specified)
    Mar 28, 2023

    Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • (no location specified)
    Aug 4, 2023

    t Pathologic Complete Response Observed in HER2 Positive Breast

    Completed
    • HER2+ Breast Cancer
    • Rawalpindi, Punjab, Pakistan
      Rawalpindi Medical University
    Jun 26, 2023

    Breast Cancer, HER2-positive Breast Cancer Trial in Toronto (Neratinib)

    Not yet recruiting
    • Breast Cancer
    • HER2-positive Breast Cancer
    • Toronto, Ontario, Canada
      University Health Network: Princess Margaret Cancer Centre
    Oct 31, 2022

    Breast Cancer, Breast Cancer Female, Breast Cancer, Male Trial in Tampa (biological, drug, procedure)

    Recruiting
    • Breast Cancer
    • +7 more
    • Dendritic Cell Vaccine (DC1)
    • +2 more
    • Tampa, Florida
      H. Lee Moffitt Cancer Center and Research Institute
    Aug 23, 2022

    Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma Trial in Washington, Baltimore, Hackensack

    Active, not recruiting
    • Breast Cancer
    • +2 more
    • Washington, District of Columbia
    • +4 more
    Jan 31, 2023

    Breast Tumors, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer Trial in United States (Z-endoxifen, exemestane,

    Recruiting
    • Breast Neoplasms
    • +3 more
    • Phoenix, Arizona
    • +3 more
    Jan 30, 2023

    Breast Cancer Trial (dalpiciclib plus letrozole)

    Not yet recruiting
    • Breast Cancer
    • dalpiciclib plus letrozole
    • (no location specified)
    Aug 21, 2022

    Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)

    Recruiting
    • Breast Cancer
    • Neoadjuvant
    • pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
    • Wuhan, Hubei, China
    • +1 more
    Aug 18, 2023

    HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab)

    Recruiting
    • HER2-positive Breast Cancer
    • Dendritic Cell (DC1) Vaccine
    • +3 more
    • Tampa, Florida
      Moffitt Cancer Center
    Dec 28, 2022

    Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

    Not yet recruiting
    • Advanced Solid Tumor
    • +8 more
    • (no location specified)
    Nov 13, 2023

    Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

    Recruiting
    • Hormone Receptor Positive HER-2 Negative Breast Cancer
      • Tuebingen, Germany
        Department of Women's Health
      Jun 1, 2023

      Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell Vaccine)

      Recruiting
      • Leptomeningeal Disease
      • +2 more
      • Dendritic Cell Vaccine
      • Tampa, Florida
        Moffitt Cancer Center
      Apr 11, 2023